Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Lanraplenib in Renal Impairment
NCT02959138Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of lanraplenib in Inflammatory Disorders (3 arms), sponsored by Gilead Sciences. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity and 1 more. Started Nov 2016; status: completed.
02
Drugs
lanraplenib
03
Conditions
Inflammatory Disorders
Beyond the preview
Go deeper on NCT02959138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02959138.